Intra-Cellular Therapies, Inc. (ITCI)
| Market Cap | 13.66B |
| Revenue (ttm) | 680.85M |
| Net Income (ttm) | -74.68M |
| Shares Out | 106.24M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,163,466 |
| Open | 128.77 |
| Previous Close | 128.54 |
| Day's Range | 128.52 - 128.77 |
| 52-Week Range | 63.30 - 128.77 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 103.92 (-19.19%) |
| Earnings Date | Feb 21, 2025 |
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of vario... [Read more]
Full Company ProfileFinancial Performance
In 2024, Intra-Cellular Therapies's revenue was $680.85 million, an increase of 46.62% compared to the previous year's $464.37 million. Losses were -$74.68 million, -46.54% less than in 2023.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ITCI stock is "Buy." The 12-month stock price forecast is $103.92, which is a decrease of -19.19% from the latest price.
News
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular T...
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
On Monday, Johnson & Johnson JNJ agreed to acquire Intra-Cellular Therapies Inc. ITCI for $132.00 per share in cash for a total equity value of approximately $14.6 billion.
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.
J&J to buy Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schi...
This Stock Is Soaring Amid J&J Takeover Report
A deal could be reached for the biotech company this week, according to a media report.
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it...
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder,...
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)